Literature DB >> 35383587

Hepatic Adenomas in Patients 60 and Older Are Enriched for HNF1A Inactivation and Malignant Transformation.

Saba Yasir1, Zongming E Chen1, Dhanpat Jain2, Sanjay Kakar3, Tsung-Teh Wu1, Matthew M Yeh4, Michael S Torbenson1.   

Abstract

Hepatic adenomas occur most commonly in women between the ages of 20 and 40 years, but rarely they occur in older aged persons, including those 60 years of age or older. This group of adenomas, however, has not been systemically examined. Twenty-six hepatic adenomas in persons 60 years of age or older were studied, along with a control group of 50 hepatic adenomas in persons aged 30 to 39. Hepatic adenomas in persons 60 or more years of age were found in 21 women and 5 men, while the control group had 44 women and 6 men. Subtyping the adenomas in persons 60 years or older showed the following results: 18 HNF1A-inactivated adenomas (69%), 4 inflammatory adenomas (15%), and 4 unclassified adenomas (15%). In contrast, the control group showed a significantly different pattern (P=0.003), with a greater percentage of inflammatory adenomas (28, 56%), fewer HNF1A-inactivated adenomas (8, 16%), and more unclassified adenomas (14, 28%). Atypia and malignant transformation within the hepatic adenomas was studied next. Of the hepatic adenomas in persons age 60 or greater, 3 (12%) showed atypical histologic features, and 6 (23%) had a malignant transformation. In contrast, for hepatic adenomas in the control group, only 4 (8%) adenomas showed atypical histologic features, and 3 (6%) had undergone malignant transformation. In addition, the hepatic adenomas that were atypical or showed early malignant transformation were less likely to have beta-catenin activation in patients over 60 (2/9 cases) compared with those between 30 and 39 years (5/7 cases). Myxoid change and heavy lipofuscin deposition were also more common in adenomas in older aged persons. In conclusion, hepatic adenomas in persons 60 years of age or older are enriched for HNF1A-inactivated adenomas and have a higher frequency of malignant transformation. Malignant transformation, however, is less likely to develop through activation of the beta-catenin pathway.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35383587      PMCID: PMC9469468          DOI: 10.1097/PAS.0000000000001892

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  28 in total

Review 1.  Hepatocellular carcinoma arising in a pigmented telangiectatic adenoma with nuclear β-catenin and glutamine synthetase positivity: case report and review of the literature.

Authors:  Jaclyn F Hechtman; Mohammad Raoufi; M Isabel Fiel; Bachir Taouli; Marcelo Facciuto; Thomas D Schiano; Amanda G Blouin; Swan N Thung
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

2.  Identification of key challenges in liver pathology: data from a multicenter study of extramural consults.

Authors:  Michael S Torbenson; Christina A Arnold; Rondell P Graham; Dhanpat Jain; Sanjay Kakar; Dora M Lam-Himlin; Bita V Naini; Tsung-Teh Wu; Matthew Yeh
Journal:  Hum Pathol       Date:  2019-03-08       Impact factor: 3.466

3.  Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon.

Authors:  Juan Putra; Linda D Ferrell; Annette S H Gouw; Valerie Paradis; Arvind Rishi; Christine Sempoux; Charles Balabaud; Swan N Thung; Paulette Bioulac-Sage
Journal:  Mod Pathol       Date:  2019-09-30       Impact factor: 7.842

4.  Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease.

Authors:  Leendert H Oterdoom; K Evelyne Verweij; Katharina Biermann; Mirjam Langeveld; Henk R van Buuren
Journal:  J Gastrointestin Liver Dis       Date:  2015-12       Impact factor: 2.008

5.  Hepatocellular Neoplasms Arising in Association With Androgen Use.

Authors:  Sounak Gupta; Bita V Naini; Richard Munoz; Rondell P Graham; Benjamin R Kipp; Michael S Torbenson; Taofic Mounajjed
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

6.  Reticulin loss in benign fatty liver: an important diagnostic pitfall when considering a diagnosis of hepatocellular carcinoma.

Authors:  Aatur D Singhi; Dhanpat Jain; Sanjay Kakar; Tsung-Teh Wu; Matthew M Yeh; Michael Torbenson
Journal:  Am J Surg Pathol       Date:  2012-05       Impact factor: 6.394

7.  Primary hepatic tumors with myxoid change: morphologically unique hepatic adenomas and hepatocellular carcinomas.

Authors:  Safia N Salaria; Rondell P Graham; Shinichi Aishima; Taofic Mounajjed; Matthew M Yeh; Michael S Torbenson
Journal:  Am J Surg Pathol       Date:  2015-03       Impact factor: 6.394

8.  Malignant transformation of hepatic adenomas.

Authors:  Shien T L Micchelli; Perumal Vivekanandan; John K Boitnott; Timothy M Pawlik; Michael A Choti; Michael Torbenson
Journal:  Mod Pathol       Date:  2008-02-01       Impact factor: 7.842

9.  Immunostains Used to Subtype Hepatic Adenomas Do Not Distinguish Hepatic Adenomas From Hepatocellular Carcinomas.

Authors:  Liping Liu; Sejal S Shah; Bita V Naini; Samuel French; Tsung-Teh Wu; Michael S Torbenson; Vishal S Chandan
Journal:  Am J Surg Pathol       Date:  2016-08       Impact factor: 6.394

10.  Giant hepatocellular carcinoma with bone metastasis in a young adult, emerged from pigmented adenoma with beta-Catenin activation: A case report.

Authors:  Sebastian Lünse; Paula Döring; Claus-Dieter Heidecke; Lars Ivo Partecke
Journal:  Int J Surg Case Rep       Date:  2017-05-03
View more
  1 in total

1.  Spontaneous Occurrence of Various Types of Hepatocellular Adenoma in the Livers of Metabolic Syndrome-Associated Steatohepatitis Model TSOD Mice.

Authors:  Wenhua Shao; Orgil Jargalsaikhan; Mayuko Ichimura-Shimizu; Qinyi Cai; Hirohisa Ogawa; Yuko Miyakami; Kengo Atsumi; Mitsuru Tomita; Mitsuko Sutoh; Shunji Toyohara; Ryoji Hokao; Yasusei Kudo; Takeshi Oya; Koichi Tsuneyama
Journal:  Int J Mol Sci       Date:  2022-10-07       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.